Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Panzitt, K; Zollner, G; Marschall, HU; Wagner, M.
Recent advances on FXR-targeting therapeutics
MOL CELL ENDOCRINOL. 2022; 552: 111678 Doi: 10.1016/j.mce.2022.111678
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Panzitt Katrin
Wagner Martin
Co-Autor*innen der Med Uni Graz
Zollner Gernot
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The bile acid receptor FXR has emerged as a bona fide drug target for chronic cholestatic and metabolic liver diseases, ahead of all non-alcoholic fatty liver disease (NAFLD). FXR is highly expressed in the liver and intestine and activation at both sites differentially contributes to its desired metabolic effects. Unrestricted FXR activation, however, also comes along with undesired effects such as a pro-atherogenic lipid profile, pruritus and hepatocellular toxicity under certain conditions. Several pre-clinical studies have confirmed the potency of FXR activation for cholestatic and metabolic liver diseases, but overall it remains still open whether selective activation of intestinal FXR is advantageous over pan-FXR activation and whether restricted or modulated FXR activation can limit some of the side effects. Even more, FXR antagonist also bear the potential as intestinal-selective drugs in NAFLD models. In this review we will discuss the molecular prerequisites for FXR activation, pan-FXR activation and intestinal FXR in/activation from a therapeutic point of view, different steroidal and non-steroidal FXR agonists, ways to restrict FXR activation and finally what we have learned from pre-clinical models and clinical trials with different FXR therapeutics.

Find related publications in this database (Keywords)
FXR
Agonists
Antagonists
Partial agonists
Steroidal agonists
Non-steroidal agonists
© Med Uni Graz • Impressum